16.04.2012 - The Polish government is to ban Monsanto's MON810 maize making it the seventh in the club of EU countries to stop cultivation of the GM crop.
Warsaw – The move follows protests in Warsaw last month by around 1,500 beekeepers and anti-GM protesters who dumped thousands of dead bees on the steps of the Ministry of Agriculture. Agriculture Minister Marek Sawicki has announced that the government would implement a ban on the cultivation of the genetically modified MON 810 maize. The minister claimed the pollen might be responsible for a host of health problems and may even be the cause of the dwindling bee population. The government now wants to pass a law that circumvents the need to obtain EU approval for a ban on any GMO crops. Revised Polish regulations would stipulate that the ban may be implemented and that it will suffice simply to notify the European Commission of the matter. “We are pleasantly surprised that the government is looking for a way of actually implementing the ban,” said Greenpeace spokesman Jacek Winiarski after having a discussion with governmental representatives. If Poland implements the ban, it will follow in the footsteps of Austria, France, Germany, Greece, Hungary and Luxembourg which have all banned the cultivation of MON 810 at different stages, saying it threatens biodiversity.
12.02.2016 The promise of the microbiome as the basis of new treatments has caught the attention of many. Now, UK biotherapeutics maker 4D pharma plc has padded its microbiome pipeline with the acquisition of Irish Tucana Health.
05.02.2016 It is not yet clear why a man died during a first-in-man clinical trial in January. A preliminary report found several “major shortcomings” by responsible CRO Biotrial. However, all regulations were complied with.
04.02.2016 After having dodged multiple takeover attempts by Monsanto last year, agrobusiness giant Syngenta has now agreed to be acquired by chemical corporation ChemChina. The Swiss company also announced plans to go public within a few years.
01.02.2016 Altering human DNA with the efficient gene editing method CRISPR/Cas9, especially germline modifications, was long considered a taboo. Now, however, UK scientists have received official approval to tinker with embryo DNA.
27.01.2016 Three UK universities have teamed up with three pharma companies to create the Apollo Therapeutics Fund. With the tech transfer fund, the consortium aims to develop scientific research into medicines.
25.01.2016 Affimed means to put a promising drug combination to the test. With support from MSD, the German biopharma will carry out clinical trials for an immunotherapy combining treatments of both companies.
21.01.2016 Stop squandering antibiotics and make research profitable again: at the World Economic Forum in Swiss Davos, 83 pharmaceutical companies have called for a unified approach towards the threat of antimicrobial resistance.